Houston pharma co. raising $139.6M through public offering, private placement


The Houston company entered the capital markets to further fund trials for its immunotherapy drug candidates.

Previous New Academy Bank branch represents the future of banking in KC, Dickinson Financial CEO says
Next Bellwether Enterprise hires Birmingham CRE finance veteran